Expanding the Source Genomics Portfolio: Launch of Alamar Biosciences Proteomics

Source Genomics now offers Alamar Proteomics, a next-generation proteomics service designed to advance biomarker discovery and early disease detection.

Many clinically relevant proteins exist at concentrations below the detection limits of conventional platforms. Alamar Bioscience overcomes this challenge, enabling the identification and quantification of ultra-low abundance proteins with exceptional precision and reproducibility.

Why Choose Alamar Biosciences Proteomics?

Ultra-Sensitive Detection

Traditional immunoassays and mass spectrometry workflows can struggle to detect low-abundance proteins, particularly in early-stage disease or minimally invasive samples. This platform captures proteins that would otherwise remain undetected, supporting early disease research, translational studies, and biomarker validation.

High Specificity and Sensitivity

Unlike traditional mass spectrometry approaches, Alamar’s NULISA™ technology delivers highly sensitive protein quantification without complex sample preparation or lengthy analytical workflows.

Highly Reproducible Data

Automated workflows and standardised processes reduce technical variability and ensure consistent performance. Researchers benefit from reliable datasets suitable for downstream validation and clinical research pathways.

High Dynamic Range

The platform measures a broad spectrum of proteins within a single assay, capturing both low- and high-abundance targets. This enables comprehensive pathway analysis and supports multi-biomarker panel development.

By partnering with Alamar Biosciences, Source Genomics are bringing ultra-sensitive, high-performance proteomics to support your research from discovery through to validation. Contact our team to learn more about integrating this service into your workflow.